The review found that the nation needed to develop a new capacity to identify and incubate promising research or discoveries to better fuel the medical countermeasure pipeline.
In response, the National Institutes of Health (NIH) will utilize new approaches to scout for promising efforts within all of the basic research that NIH supports and find the projects that could also be developed as medical countermeasures to protect people against chemical, biological, radiological/nuclear threats. This research will be closely monitored so when appropriate it can be swiftly transitioned to BARDA for advanced development and over to FDA to consider for approval.
NIH’s National Institute of Allergy and Infectious Disease developed criteria for evaluating this promising research. Already, initial products have been identified and a report of selected products will be issued in 2012.